EmpraSan Sovereign, 2.82% w/v, Concentrate for Teat Dip / Teat Spray Solution

Summary of Product characteristics

                                Issued 09/06/2010 – AN 00667/2009
1/3
SUMMARY OF PRODUCT CHARACTERISTICS
1) Name of the veterinary medicinal product
EmpraSan Sovereign, 2.82% w/v, Concentrate for Teat Dip / Teat Spray
Solution
2) Qualitative and Quantitative composition
Active Substance: 2.82% w/v minimum available Iodine
Other Constituents:
22.79% w/v Glycerol
3.8 %w/v Ethoxylated Lanolin
For full list of excipients see section 6.1
3) Pharmaceutical form
Concentrate for Teat Dip / Teat Spray Solution
Description: Mobile brown liquid
4) Clinical particulars
4.1 Target species
Lactating dairy cattle.
4.2 Indications for use, specifying the target species
As an aid in the prevention of mastitis in lactating dairy cattle.
After each milking the diluted
product is applied directly to the teats by spraying or by teat
dipping with a teat cup.
4.3 Contra-indications
None
4.4 Special warnings for each target species
For external use only. Teat dip cups should be emptied after each
milking and washed thoroughly
before re-use. Wash and dry udders and teats before next milking.
4.5 Special precautions for use
i) Special precautions for use in animals
None
ii) Special precautions to be taken by the person administering the
medicinal product to animals
CONCENTRATE
The following safety phrases refer to the concentrated product only
and do not apply once the
product is diluted to the working solution: Risk of serious damage to
eyes. Wear eye/face
protection when preparing the dip or spray.
DILUTED WORKING SOLUTION
When using as a spray, avoid working in spray mist.
Avoid contact with eyes.
In case of contact with eyes, rinse immediately with plenty of water
and seek medical advice.
If swallowed, seek medical advice immediately and show this container
or label.
Hands and exposed skin should be washed after using this product.
Keep away from food, drink and animal feedstuffs.
Do not eat, drink or smoke whilst using the product
Issued 09/06/2010 – AN 00667/2009
2/3
4.6 Adverse reactions (frequency and seriousness)
None noted.
4.7 Use during pregnancy, and la
                                
                                Read the complete document